Bladder cancerBladder cancer molecular biomarkers and guideline recommendationsBladder cancer sample requirements, testing methods, and opportunitiesCarcinoma in situ risk-stratification infographic

Bladder cancer molecular biomarkers and guideline recommendations

Biomarker testing can inform optimal biomarker testing selection for patients. Review guideline-recommended treatment for bladder cancer.

Download Resource

Bladder cancer sample requirements, testing methods, and opportunities

Review the types of biomarker tests that are currently recommended by professional guidelines and explore novel testing methods that are being developed to overcome current gaps in clinical practice.

Download Resource

Carcinoma in situ risk-stratification infographic

Learn about how CIS (carcinoma in situ) contributes to high risk in NMIBC (non-muscle invasive bladder cancer)4, implications for management, and best practices for appropriate treatment.

Download Resource

References

  1. Mohanty SK, Lobo A, Mishra SK, et al. Precision medicine in bladder cancer: present challenges and future directions. J Pers Med. 2023;13(5):756.
  2. Luceno CF, Jeon WJ, Samaeekia R, et al. Precision medicine to treat urothelial carcinoma – the way forward. Cancers (Basel). 2023;15(11):3024.
  3. Yu SH, Kim SS, Kim S, et al. FGFR3 mutations in urothelial carcinoma: a single-center study using next-generation sequencing. J Clin Med. 2024;13(5):1305.
  4. Llano A, Chan A, Kuk C, et al. Carcinoma in situ (CIS): is there a difference in efficacy between various BCG strains? a comprehensive review of the literature. Cancers (Basel). 2024:16(2):245.